drugset / Trial / NCT03235921

Use of Nitroglycerine to Improve Signs of Poor Peripheral Perfusion in Patients With Traumatic Hemorrhagic Shock

NCT03235921

Phase 2 Unknown 100 enrolled Assiut University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Hemorrhagic shock is a pathologic state in which intravascular volume and oxygen delivery are impaired. During circulatory failure associated with hypovolemia and low cardiac output, redistribution of blood flow caused by increased vasoconstriction results in decreased perfusion of the skin. Skin temperature and capillary refill time has been advocated as a measure of peripheral perfusion.

Timeline

Start
2016-03
Primary completion
2017-08
Completion
2017-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitroglycerin Unknown 5 mg Topical

Indications

No indication recorded.